Clinical Network Services (CNS), an integrated product development company based in Australia, New Zealand and the U.K., providing planning, implementation and delivery of preclinical through phase II trials, has established an office in the U.S. CNS also has appointed Megan Hill business development manager in the U.S.
Initially based out of San Francisco, Calif., CNS U.S. will complement its BioDesk services’ established regulatory/product development consultancy services in Australia and Europe and will enable Biodesk to better support its clients seeking to engage with the FDA.
Mark Reid, director of BioDesk and regulatory affairs, said, “It is a very exciting time at CNS currently, and particularly for our BioDesk services. In the last 12 months, we have responded to client requests to provide a broader and deeper international scope to our established BioDesk brand. Last year we launched in Europe and have successfully grown a strong team in Europe. Establishing CNS U.S. now provides BioDesk with a new platform from which it can continue to respond to that demand and provide integrated access to the FDA. It is incredibly important that we provide genuine expertise in the major regulatory environments.”